Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab in HR-MGUS or NHR-SMM
NCT06140524Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- May 2032
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of linvoseltamab in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) (5 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Adverse Events of Interest at 35 days, Treatment-Emergent Adverse Events at 35 days and 2 more. Started Sep 2024; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
monoclonal gammopathy of undetermined significance (MGUS)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT06140524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06140524.